undamentalytics Newsletter
Sign in

Aligos Therapeutics, Inc. revenue

Aligos Therapeutics, Inc.'s revenue was $2.2m in fiscal 2025, down 39.5% on the year before. Over the last twelve months it was $3.7m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0006,1913,6112,1863,740
Growth on the year before————−41.7%−39.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Aligos Therapeutics, Inc. $3.7m 19.4% -5.5%
Dyadic International Inc $3.8m -8.0% 3.4%
DBV Technologies S.a. $3.8m -31.6% -11.6%
Camp4 Therapeutics Corp $4.2m 40.2% —
Xenetic Biosciences, Inc. $3.3m 33.3% 14.7%
Curis Inc $4.3m -62.2% -25.0%

Compare with peers

Head to head: ALGS vs DYAIALGS vs DBVTALGS vs CAMPALGS vs XBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aligos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aligos Therapeutics, Inc.